Menu Search
Equities

Strides Pharma Science Ltd

STAR:NSI

Strides Pharma Science Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,504.25
  • Today's Change4.25 / 0.28%
  • Shares traded193.88k
  • 1 Year change+209.42%
  • Beta1.1006
Data delayed at least 15 minutes, as of Nov 22 2024 10:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 2 analysts offering 12 month price targets for Strides Pharma Science Ltd have a median target of 1,877.00, with a high estimate of 1,954.00 and a low estimate of 1,800.00. The median estimate represents a 24.06% increase from the last price of 1,513.00.
High29.1%1,954.00
Med24.1%1,877.00
Low19.0%1,800.00

Dividends

In 2024, Strides Pharma Science Ltd reported a dividend of 2.50 INR, which represents a 66.67% increase over last year. The analyst covering the company expects dividends of 3.50 INR for the upcoming fiscal year, an increase of 40.00%.
Div growth (TTM)66.67%
More ▼

Earnings history & estimates in INR

On Jan 24, 2023, losses of -13.46 per share.
The next earnings announcement is expected on May 20, 2025.
Average growth rate-52.87%
Strides Pharma Science Ltd reported annual 2024 earnings of 13.01 per share on May 22, 2024.
Average growth rate+44.24%
More ▼

Revenue history & estimates in INR

Strides Pharma Science Limited had 2nd quarter 2025 revenues of 12.01bn. This bettered the 11.58bn consensus of the 2 analysts covering the company. This was 29.15% above the prior year's 2nd quarter results.
Average growth rate+4.77%
Strides Pharma Science Limited had revenues for the full year 2024 of 40.51bn. This was 9.83% above the prior year's results.
Average growth rate+10.76%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.